Sepio Capital LP trimmed its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 5.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 216,075 shares of the healthcare product maker's stock after selling 13,622 shares during the period. Abbott Laboratories accounts for 2.0% of Sepio Capital LP's portfolio, making the stock its 9th largest holding. Sepio Capital LP's holdings in Abbott Laboratories were worth $24,440,000 at the end of the most recent quarter.
Several other hedge funds also recently bought and sold shares of ABT. Titleist Asset Management LLC raised its position in shares of Abbott Laboratories by 38.2% during the fourth quarter. Titleist Asset Management LLC now owns 3,437 shares of the healthcare product maker's stock valued at $389,000 after buying an additional 950 shares during the last quarter. Quadrant Capital Group LLC lifted its stake in Abbott Laboratories by 0.3% in the 4th quarter. Quadrant Capital Group LLC now owns 34,773 shares of the healthcare product maker's stock worth $3,933,000 after purchasing an additional 91 shares in the last quarter. Ilmarinen Mutual Pension Insurance Co boosted its holdings in shares of Abbott Laboratories by 25.1% during the 4th quarter. Ilmarinen Mutual Pension Insurance Co now owns 264,500 shares of the healthcare product maker's stock valued at $29,918,000 after purchasing an additional 53,000 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Abbott Laboratories by 5.9% in the fourth quarter. Russell Investments Group Ltd. now owns 1,117,790 shares of the healthcare product maker's stock worth $126,421,000 after purchasing an additional 62,533 shares during the last quarter. Finally, Rahlfs Capital LLC bought a new position in Abbott Laboratories during the fourth quarter valued at approximately $1,047,000. Institutional investors own 75.18% of the company's stock.
Insider Activity at Abbott Laboratories
In other news, SVP Eric Shroff sold 562 shares of the company's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $138.17, for a total transaction of $77,651.54. Following the transaction, the senior vice president now directly owns 31,970 shares of the company's stock, valued at approximately $4,417,294.90. This represents a 1.73 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Andrea F. Wainer sold 949 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $138.17, for a total value of $131,123.33. Following the transaction, the executive vice president now directly owns 74,381 shares in the company, valued at $10,277,222.77. This represents a 1.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 116,449 shares of company stock valued at $15,463,316 over the last quarter. 0.46% of the stock is owned by corporate insiders.
Abbott Laboratories Trading Up 2.4 %
Shares of Abbott Laboratories stock traded up $3.01 on Friday, hitting $127.51. 2,688,830 shares of the company traded hands, compared to its average volume of 5,978,970. Abbott Laboratories has a 52 week low of $99.71 and a 52 week high of $141.23. The company has a market cap of $221.14 billion, a PE ratio of 16.65, a PEG ratio of 2.52 and a beta of 0.80. The stock's 50 day moving average price is $130.80 and its 200-day moving average price is $121.24. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32.
Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share for the quarter, hitting the consensus estimate of $1.34. The business had revenue of $10.97 billion during the quarter, compared to analysts' expectations of $11.03 billion. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The business's revenue for the quarter was up 7.2% compared to the same quarter last year. During the same period in the prior year, the business earned $1.19 EPS. Equities research analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.
Abbott Laboratories Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be given a dividend of $0.59 per share. The ex-dividend date is Tuesday, April 15th. This represents a $2.36 annualized dividend and a yield of 1.85%. Abbott Laboratories's dividend payout ratio (DPR) is presently 30.85%.
Analysts Set New Price Targets
ABT has been the topic of several recent research reports. Stifel Nicolaus upped their price objective on Abbott Laboratories from $130.00 to $135.00 and gave the stock a "buy" rating in a report on Thursday, January 23rd. Barclays reiterated an "overweight" rating and set a $158.00 price objective (up previously from $149.00) on shares of Abbott Laboratories in a research report on Monday, January 27th. Bank of America upped their target price on shares of Abbott Laboratories from $133.00 to $150.00 and gave the company a "buy" rating in a research report on Monday, March 10th. Argus upgraded Abbott Laboratories to a "strong-buy" rating in a research report on Tuesday, January 28th. Finally, StockNews.com cut Abbott Laboratories from a "strong-buy" rating to a "buy" rating in a report on Wednesday, February 12th. Four analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Abbott Laboratories presently has an average rating of "Moderate Buy" and a consensus price target of $137.94.
Read Our Latest Report on ABT
About Abbott Laboratories
(
Free Report)
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Recommended Stories
Before you consider Abbott Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.
While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
